Radioisotope Guided Sentinel Lymph Node Dissection in Prostate Cancer: Rate of Lymph Node Involvement Depending on Preoperative Tumor Characteristics in More Than 2,100 Patients

Alexander Winter1*, Svenja Engels1, Marie-Christin Süykers1, Rolf-Peter Henke1 and Friedhelm Wawroschek1
1University Hospital for Urology, Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University, Oldenburg, Oldenburg, Germany
2Institute of Pathology Oldenburg, Oldenburg, Germany

Abstract

Background: Extended pelvic lymph node dissection is the gold standard for lymph node staging in prostate cancer. Sentinel lymph node dissection has replaced extended lymphadenectomy in several tumors. The aim of the study was to stratify the rate of lymph node involvement in prostate cancer patients undergoing radio guided sentinel lymph node dissection depending on preoperative tumor characteristics.

Methods: We analyzed 2,102 prostate cancer patients (median age 67 years, IQR 62-71 years) who underwent radioisotope guided sentinel lymphadenectomy and retroperitoneal radical prostatectomy between January 2005 and February 2015 in a retrospective single center study. Median prostate specific antigen was 7.8 ng/ml (IQR 5.5-12.7 ng/ml). 99mTechnetium nanocolloid (ca. 200 MBq) was transrectally injected into the prostate. A few hours later scintigraphy was carried out. Sentinel lymph nodes were intraoperatively detected using a gamma probe. The rate of lymph node invasion was analyzed for D’Amico risk groups and in relation to biopsy Gleason scores.

Results: The median number of lymph nodes removed was 10 (IQR 7-13). Overall, 19.3% of patients (n=405) had lymph node involvement; 2.9% (n=16) in low, 15.6% (n=139) in intermediate and 42.0% (n=248) in high risk disease. 64 (6.5%) of 984 patients with Gleason score ≤6 prostate cancer were lymph node positive; 20.6% (n=154) of 742 in patients with Gleason score 7 (3+4; 4+3) and 57.5% (n=103) in Gleason score ≥8 prostate cancer.

Conclusion: We present the largest study on sentinel lymph node dissection in prostate cancer patients until now. The rate of lymph node invasion was higher in the examined sentinel collective than expected according to extended lymphadenectomy series. These results demonstrate the reliability and high sensitivity of sentinel lymphadenectomy for the detection of lymph node metastases in prostate cancer patients.

Introduction

PLND is still the gold standard for LN staging in clinically localized prostate cancer. The diagnostic accuracy of available imaging procedures is quite inferior to the histological verification of LN metastases. The LN status is a crucial prognostic factor in prostate cancer. Presence and extension of LNI is associated with an increased risk of systemic dissemination and progression of the disease. Moreover, the role of PLND as a therapeutic intervention has been the focus of renewed interest. Several reports indicate that PLND improves biochemical relapse-free survival, especially in patients with minimal lymphatic dissemination [1,2]. LNI prevalence is directly related to the number of dissected LNs and extent of the PLND [3,4]. There is general consensus that an ePLND achieves the highest staging accuracy. However, the rate of complications rises along with the number of LNs removed [5-7].

Because of therapeutic consequences, the high expenditure of time and the increased complication rate of the ePLND and due to the low detection rate of limited PLND procedures, in 1999, Wawroschek et al. started to transfer techniques and concepts of the SLN identification in other tumor entities to prostate cancer [8,9].

The clinical impact of the so-called SLN is based on the phenomenon of a primary lymphatic filter level of the tumor beyond further lymphatic spread into the adjacent LNs takes place, suggesting that a negative SLN excludes lymphatic metastasis. The sentinel technique in prostate cancer differs from those in other tumor entities. In breast cancer, malignant melanoma and penile cancer [10], a well-directed peritumoral injection is only placed to observe the lymphatic drainage of...
the tumor and the first draining LN. In prostate cancer, which occurs commonly multifocal, it is unknown with absolute certainty from which part of the organ the metastatic spread originates. Therefore, the goal of prostate lymph scintigraphy must be the imaging of all primary draining LNs of the prostate, under which the SLN of cancer also exist. Wawroschek et al. stated that all pre-operatively and intraoperatively identified gamma radiation-active nodes would be defined as SLN [8,9]. The same working group has shown that the most frequent location of SLN was the external and internal iliac region (32.3%; 30.9%), followed by the obturator fossa (26.5%), the presacral (5.7%), and other regions [11].

Presently, different new tracers, such as the near-infrared fluorescent dye ICG in connection with robotic [12], laparoscopic [13], and open radical prostatectomies [14], and magnetic nanoparticles [15] are being tested for marking and intraoperative detection of SLNs. In all of these studies the intra-prostatic sentinel tracer injection did not cause any problems to the operation.

Since 2005 the Oldenburg working group has gained experience in more than 2,100 prostate cancer cases who underwent a radio guided sPLND together with a radical retropubic prostatectomy. In this study we present the largest study on radio guided sPLND in prostate cancer patients until now. We stratify the rate of LNI in prostate cancer patients undergoing sPLND depending on preoperative tumor characteristics.

Materials and Methods

Patients

A total of 2,113 consecutive prostate cancer patients (cT1, cT2, and cT3) were identified, who underwent sPLNDs in combination with radical retropubic prostatectomy carried out by four highly experienced surgeons in a single center between January 2005 and February 2015. Patients with incomplete clinical information for PSA, clinical stage, or biopsy Gleason score (n=11; 0.5%) were excluded. The final sample included 2,102 patients. All patients had been informed verbally and in writing about a sPLND and radical retropubic prostatectomy and signed a consent form.

sPLND technique

The sPLND technique was applied as described by Wawroschek et al. [9]. 99mTechnetium nanocolloid was transrectally injected 24 hours before surgery into the prostate under ultrasound guidance. Three injections were done per prostate lobe. Activity attained about 100 MBq per lobe and total injection volume was about 1.2 mL. A few hours after injection, scintigraphy was carried out.

The radioactivity of the LNs was intraoperatively measured using two different gamma probe systems (C-Trak System, Care Wise, Morganhill, CA, USA; Crystal Probe SG04, Crystal Photonics GmbH, Berlin, Germany). The two systems were used separately and have comparable characteristics (e.g. sensitivity) [16]. LNs identified as SLNs by the gamma probe were dissected. For surgical reasons, LNs other than SLNs directly adjoining and adhering to SLNs were also removed, if an in-situ separation was not possible. Furthermore, in the case of SLNs in the obturator fossa area, the surrounding non-radioactive lymphatic tissue of the fossa was also dissected. However, lymphatic tissue of the fossa was not resected, if no SLN existed in the fossa area.

In prostate cancer, the radiation exposure to the operating surgeons due to SLN detection in the operating room (ca. 2.3 µSv) is comparable to the small exposure in breast cancer [17]. Therefore, the staff in the operating room is not to be considered as occupationally exposed to radiation (critical value: 1 mSv / year).

Histopathological examination

All LNs were initially cut in 3 mm transverse sections, routinely processed and completely embedded in paraffin; 4–5 µm thick sections were stained with hematoxylin-eosin. Selected cases of serial sections were analysed. Immunohistochemistry with a pancytokeratin antibody (AE1/AE3) was carried out to confirm or exclude metastatic spread in rare cases with inconclusive conventional histology.

Measurement

The rate of patients with LNI was analyzed in total as well as for D’Amico risk groups: low-risk (PSA <10ng/ml and/or Gleason score <6 and/or ≤cT2a), intermediate-risk (PSA 10–20 ng/ml and/or Gleason score 7 and/or cT2b) and high-risk prostate cancer (PSA >20 ng/ml and/or Gleason score 8–10 and/or ≥T2c). The rate of patients with LNI was also calculated under consideration of the biopsy Gleason score.

Results

Table 1 lists the summary of patient characteristics and details to the incidence of LNI depending on preoperative and postoperative tumour stage and Gleason sum. The median number of LNs removed was 10 (IQR 7–13). The median number of positive LNs per patient was 2 (IQR 1–3). Overall, 19.3% of patients (n=405) had LNI.

The incidence of LNI patients depending on D’Amico risk groups ranged from 2.9% (low risk) to 42.0% in high risk prostate cancer patients. The distribution of the risk groups of the examined population can be found in Figure 1.

In consideration of the biopsy Gleason score, 6.5% of the patients with Gleason score ≥6 were LN positive. Regarding the patients with

Figure 1: Incidence of patients with lymph node involvement depending on preoperative tumor characteristics (D’Amico risk groups) and distribution of risk groups of the examined collective. GS: Gleason score.
cases with LNI [26]. The EAU guidelines suggest that PLND might at the expense of proof or removal of LN metastases in 12% of the if it leads to waiving 50% of the PLNDs prior to radical prostatectomy National Comprehensive Cancer Network deems a cut-off acceptable risk prostate cancer [24,25]. However, there is no consensus on the candidates for extended PLND as patients with intermediate or high and the potential morbidity of the PLND guidelines recommend data of ePLND series (Table 3).

The false negative rate was shown to correlate with the Gleason score. especially patients with minimal LNI appear to benefit from removal of lymph node metastases [27].

There is general consensus that extended PLND achieves the highest accuracy for LN staging in prostate cancer patients. However, the staging benefit of ePLND is accompanied by the potential risk of morbidity. Therefore, sentinel guided LN dissection has replaced the staging benefit of ePLND is accompanied by the potential risk of morbidity. Therefore, sentinel guided LN dissection has replaced the staging benefit of ePLND is accompanied by the potential risk of morbidity. Therefore, sentinel guided LN dissection has replaced the staging benefit of ePLND is accompanied by the potential risk of morbidity. Therefore, sentinel guided LN dissection has replaced the staging benefit of ePLND is accompanied by the potential risk of morbidity. Therefore, sentinel guided LN dissection has replaced the staging benefit of ePLND is accompanied by the potential risk of morbidity. Therefore, sentinel guided LN dissection has replaced the staging benefit of ePLND is accompanied by the potential risk of morbidity. Therefore, sentinel guided LN dissection has replaced the staging benefit of ePLND is accompanied by the potential risk of morbidity. Therefore, sentinel guided LN dissection has replaced the staging benefit of ePLND is accompanied by the potential risk of morbidity. Therefore, sentinel guided LN dissection has replaced the staging benefit of ePLND is accompanied by the potential risk of morbidity. Therefore, sentinel guided LN dissection has replaced the staging benefit of ePLND is accompanied by the potential risk of morbidity. Therefore, sentinel guided LN dissection has replaced

<table>
<thead>
<tr>
<th>Table 1: Patient characteristics.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathologic stage</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Gleason score 7 (3+4, respectively 4+3), 20.6% and 44.2% were LN positive. Patients with Gleason score ≥ 8 prostate cancer showed LN metastases in 57.5% of cases. Table 2 shows the number of patients, LNs and LN metastases in relation to biopsy Gleason score in detail.

<table>
<thead>
<tr>
<th>Table 2: Number of patients, lymph nodes and lymph node metastases in relation to biopsy Gleason score.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gleason score</td>
</tr>
<tr>
<td>≤ 6</td>
</tr>
<tr>
<td>7 (3+4)</td>
</tr>
<tr>
<td>7 (4+3)</td>
</tr>
<tr>
<td>≥ 8</td>
</tr>
</tbody>
</table>

In order to find a compromise between a reliable LN staging and the potential morbidity of the PLND guidelines recommend candidates for extended PLND as patients with intermediate or high risk prostate cancer [24,25]. However, there is no consensus on the risk-level of a LNI that would be the ideal cut-off. For instance, the National Comprehensive Cancer Network deems a cut-off acceptable if it leads to waiving 50% of the PLNDs prior to radical prostatectomy at the expense of proof or removal of LN metastases in 12% of the cases with LNI [26]. The EAU guidelines suggest that PLND might be spared in patients with <5% risk of LNI calculated by a nomogram based on extended PLND [20,22]. We have not yet defined a cut-off for choosing a sPLND. In view of the low morbidity of sPLNDs in combination with the high sensitivity of proof of metastases, we question the ability to define a cut-off. One should also note that especially patients with minimal LNI appear to benefit from removal of lymph node metastases [27].

On the other side, the sentinel approach is also subject to limitations. One problem with this technique is that when LNs are fully metastasized or lymph pathways are blocked, the afferent lymph will be directed to other LNs/ non-sentinel LNs [28]. These nodes will not be positive on SLN imaging, resulting in false negative findings. The false negative rate was shown to correlate with the Gleason score. Patients with a high-risk disease could thus have both positive SLNs and positive non-SLNs [29]. If the goal in such cases is to remove all pelvic LN metastases, high risk patients have the option of undergoing a combination of a sPLND and an ePLND. As such, the possibility of an ePLND overlooking a part of the LN metastases, possibly in the pre-sacral region, is overcome by being able to detect it through the sPLND. Reportedly, Joniau et al. [30] did not detect 13% of metastatic LNs by applying only an ePLND.

The radioisotope guided sentinel technique also has specific drawbacks. This procedure depends on the availability of nuclear medicine and radio tracers, which in recent years have been problematic because of cutbacks in production. Furthermore, the use of radioisotope exposes patients and healthcare workers to radiation and is heavily controlled by legislation. This calls for the development of new, simpler, radiation-free, but accurate methods, for SLN marking and intraoperative detection - especially those that for SLN marking and intraoperative detection - especially those that for SLN marking and intraoperative detection - especially those that for SLN marking and intraoperative detection - especially those that for SLN marking and intraoperative detection - especially those that for SLN marking and intraoperative detection - especially those that for SLN marking and intraoperative detection - especially those that for SLN marking and intraoperative detection - especially those that for SLN marking and intraoperative detection - especially those that for SLN marking and intraoperative detection - especially those that for SLN marking and intraoperative detection - especially those that
fluorescence labeling of SLNs it has to be consider that this approach is principally restricted by the limited tissue penetration of near-infrared fluorescence signals (< 1 cm) and the functional properties of the currently used free ICG [31]. Functionally, ICG is a rapidly clearing lymphatic perfusions marker, which does not remain in the SLNs like the radioiodid and/or is not absorbed there like the latter by macrophages. Coupled procedures (ICG-99mTechnetium nanocolloid) are either quite extensive or again involve radioactivity.

Conclusion

This analysis represents the largest study on SLN dissection in prostate cancer patients until now. Compared with the results of ePLND series, the higher rate of LN positive patients particularly in the low and intermediate risk groups underpins the sensitivity of the sentinel approach. This data and the promising results of studies with new and radiation-free tracers that can be used by an urologist alone, speak clearly to the future viability of the sentinel technology in prostate cancer.

References

